Drug Profile


Alternative Names: GSK 2696266; RSC 649266; S 649266

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Shionogi
  • Class Antibacterials; Cephalosporins
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gram-negative infections

Most Recent Events

  • 17 Apr 2017 Shionogi announces intention to submit NDA to the US FDA in 2017 and MAA to the EMA for Gram-negative infections in 2018
  • 17 Jan 2017 Shionogi plans a phase III trial for Gram negative infections (NCT03032380)
  • 12 Jan 2017 Efficacy and adverse events data from a phase II trial in Gram negative infections released by Shionogi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top